2026-10-12T20:48:00Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33992593 2026-09-25T04:30:06Z category_388 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Impact of post-resistance molecular retesting strategies on treatment timeliness and clinical outcomes in EGFR-mutant advanced NSCLC: a real-world study.docx Wenting Zhang (342162) Feng Cheng (124653) Ping Lin (146330) Jinhe Xu (12010934) Ying Chen (9697) Jiaqi Meng (6111086) Xiulian Huang (25107367) Wen Wen (596162) Zhongquan Zhao (556760) Yingfang Song (25107370) Lei Zhang (38117) Zongyang Yu (6566321) Oncology and Carcinogenesis not elsewhere classified circulating tumor DNA EGFR mutation non-small cell lung cancer real-world study time to treatment initiation Objective<p>To evaluate the association of ctDNA-based molecular retesting with treatment timeliness and clinical outcomes in patients with advanced EGFR-mutant NSCLC after first-line EGFR-TKI resistance.</p>Patients and methods<p>We retrospectively analyzed patients with advanced EGFR-mutant NSCLC who had radiologically confirmed progression after first-line EGFR-TKIs between 2019 and 2024. Patients were classified as no retesting (n=86), tissue NGS (n=94), or ctDNA testing (n=49). Primary endpoints were second-line progression-free survival (2L-PFS) and overall survival from initiation of second-line therapy (2L-OS). Secondary endpoints included time to treatment initiation (TTI) and treatment patterns. Survival was analyzed using Kaplan–Meier and log-rank methods; Cox models were used for exploratory subgroup analyses. A 1:1:1 propensity score–matched analysis and sensitivity analyses restricted to patients who initiated second-line therapy within 28 or 30 days after progression were performed.</p>Results<p>Among 229 patients, median TTI was shorter with ctDNA than tissue NGS (11.0 vs. 20.5 days, P < 0.001). Subsequent targeted therapy was most frequently used in the ctDNA group (95.9%), followed by the tissue NGS (89.4%) and no-retesting groups (81.4%; P = 0.039). After matching, median 2L-PFS was 5.0, 9.0, and 9.0 months in the no-retesting, tissue NGS, and ctDNA groups, respectively (overall P = 0.005). Median 2L-OS was 12.0, 20.0, and 19.0 months, respectively (overall P = 0.074). No significant differences in 2L-PFS or 2L-OS were observed between ctDNA and tissue NGS, and findings were consistent in 28- and 30-day sensitivity analyses.</p>Conclusions<p>Compared with tissue NGS, ctDNA testing was associated with shorter TTI, with no significant differences in 2L-PFS or 2L-OS. The ctDNA group had the highest observed targeted therapy use.</p> 2026-09-25T04:30:06Z Dataset Dataset 10.3389/fonc.2026.1969822.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Impact_of_post-resistance_molecular_retesting_strategies_on_treatment_timeliness_and_clinical_outcomes_in_EGFR-mutant_advanced_NSCLC_a_real-world_study_docx/33992593 CC BY 4.0